SI2904092T1 - Ingredients and procedures for the production of glycoproteins - Google Patents

Ingredients and procedures for the production of glycoproteins Download PDF

Info

Publication number
SI2904092T1
SI2904092T1 SI201330877T SI201330877T SI2904092T1 SI 2904092 T1 SI2904092 T1 SI 2904092T1 SI 201330877 T SI201330877 T SI 201330877T SI 201330877 T SI201330877 T SI 201330877T SI 2904092 T1 SI2904092 T1 SI 2904092T1
Authority
SI
Slovenia
Prior art keywords
seq
amino acid
acid sequence
igg1 antibody
region
Prior art date
Application number
SI201330877T
Other languages
English (en)
Slovenian (sl)
Inventor
Amit Varma
James Cuenca
Ying Zhu
Original Assignee
Abbvie Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of SI2904092T1 publication Critical patent/SI2904092T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
SI201330877T 2012-10-01 2013-09-27 Ingredients and procedures for the production of glycoproteins SI2904092T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261708554P 2012-10-01 2012-10-01
EP13776656.4A EP2904092B1 (en) 2012-10-01 2013-09-27 Compostions and methods for producing glycoproteins
PCT/US2013/062410 WO2014055370A1 (en) 2012-10-01 2013-09-27 Compostions and methods for producing glycoproteins

Publications (1)

Publication Number Publication Date
SI2904092T1 true SI2904092T1 (en) 2018-01-31

Family

ID=49354940

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330877T SI2904092T1 (en) 2012-10-01 2013-09-27 Ingredients and procedures for the production of glycoproteins

Country Status (28)

Country Link
US (2) US20150259425A1 (OSRAM)
EP (1) EP2904092B1 (OSRAM)
JP (1) JP6351598B2 (OSRAM)
KR (1) KR102182885B1 (OSRAM)
CN (1) CN104797707A (OSRAM)
AU (1) AU2013327681B2 (OSRAM)
BR (1) BR112015007319B1 (OSRAM)
CA (1) CA2886753C (OSRAM)
CY (1) CY1119602T1 (OSRAM)
DK (1) DK2904092T3 (OSRAM)
EA (1) EA201590550A1 (OSRAM)
ES (1) ES2646594T3 (OSRAM)
HK (1) HK1207394A1 (OSRAM)
HR (1) HRP20171753T1 (OSRAM)
HU (1) HUE034896T2 (OSRAM)
IL (1) IL237916A0 (OSRAM)
IN (1) IN2015DN02630A (OSRAM)
LT (1) LT2904092T (OSRAM)
ME (1) ME02882B (OSRAM)
MX (1) MX366106B (OSRAM)
NO (1) NO2760138T3 (OSRAM)
PL (1) PL2904092T3 (OSRAM)
PT (1) PT2904092T (OSRAM)
RS (1) RS56641B1 (OSRAM)
SG (2) SG10201702448WA (OSRAM)
SI (1) SI2904092T1 (OSRAM)
SM (1) SMT201700588T1 (OSRAM)
WO (1) WO2014055370A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2016070089A2 (en) * 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
MX2018008448A (es) * 2016-01-06 2019-05-30 Oncobiologics Inc Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.
JP6674028B2 (ja) * 2016-01-06 2020-04-01 アウトルック セラピューティクス，インコーポレイティド モノクローナル抗体組成物中のアフコシル化種の調節
CA3013336A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
CN108925137A (zh) 2016-02-22 2018-11-30 新加坡科技研究局 细胞培养基
EP3538151B1 (en) * 2016-11-11 2024-06-26 Whitehead Institute for Biomedical Research Human plasma-like medium
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
CN112566643A (zh) 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
KR20220002963A (ko) * 2019-04-18 2022-01-07 얀센 바이오테크 인코포레이티드 시알릴화된 당단백질
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
CN113337562B (zh) * 2021-05-24 2022-06-03 宁波人健药业集团股份有限公司 使用CHO细胞高效发酵生产rhCG的方法
CN113480632B (zh) * 2021-07-30 2023-02-03 宁波人健药业集团股份有限公司 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE60230858D1 (de) * 2001-02-15 2009-03-05 Centocor Inc Chemisch definiertes medium für kultivierte säugerzellen
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005092073A2 (en) 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
ES2411907T3 (es) 2007-08-03 2013-07-09 Facet Biotech Corporation Uso terapéutico de anticuerpos antirreceptor TWEAK

Also Published As

Publication number Publication date
SG10201702448WA (en) 2017-04-27
NO2760138T3 (OSRAM) 2018-08-04
BR112015007319B1 (pt) 2022-02-15
CA2886753A1 (en) 2014-04-10
EP2904092A1 (en) 2015-08-12
AU2013327681B2 (en) 2019-01-24
US20170152540A1 (en) 2017-06-01
CY1119602T1 (el) 2018-04-04
SG11201502339YA (en) 2015-04-29
RS56641B1 (sr) 2018-03-30
CN104797707A (zh) 2015-07-22
KR20150063441A (ko) 2015-06-09
EA201590550A1 (ru) 2015-09-30
DK2904092T3 (en) 2017-12-11
EP2904092B1 (en) 2017-09-20
ES2646594T3 (es) 2017-12-14
IL237916A0 (en) 2015-05-31
KR102182885B1 (ko) 2020-11-25
ME02882B (me) 2018-04-20
SMT201700588T1 (it) 2018-01-11
PT2904092T (pt) 2017-12-06
BR112015007319A2 (pt) 2017-08-08
US20150259425A1 (en) 2015-09-17
LT2904092T (lt) 2017-12-11
CA2886753C (en) 2021-01-26
HRP20171753T1 (hr) 2017-12-29
JP6351598B2 (ja) 2018-07-04
MX366106B (es) 2019-06-27
HUE034896T2 (hu) 2018-03-28
MX2015004027A (es) 2015-10-29
IN2015DN02630A (OSRAM) 2015-09-18
HK1207394A1 (en) 2016-01-29
AU2013327681A1 (en) 2015-04-09
PL2904092T3 (pl) 2018-02-28
JP2015532096A (ja) 2015-11-09
WO2014055370A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
SI2904092T1 (en) Ingredients and procedures for the production of glycoproteins
AR132549A2 (es) Medio de cultivo para células cho libre de suero que comprende ornitina y putrescina, método para cultivar células cho y método in vitro para producir una proteína
JP2015532096A5 (OSRAM)
ES2833471T3 (es) Cultivo celular metabólicamente optimizado
HRP20191409T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
EA201900326A1 (ru) Усовершенствованные способы повышения продуктивности антител в культурах клеток млекопитающих и сведения к минимуму агрегации в процессах выделения и очистки, получения композиций и стабильные композиции антител, полученные этими способами
ES2743903T3 (es) Métodos para cambiar el perfil isoeléctrico de un producto proteico y sus usos
HRP20171701T1 (hr) Metode za poboljšanu proizvodnju proteina
NZ597742A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
JP2017500017A5 (OSRAM)
RU2013152982A (ru) Способ снижения гетерогенности антител и способ получения соответствующих антител
MX366910B (es) Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
CY1118734T1 (el) Μεθοδοι παρασκευης γλυκοπρωτεϊνων σε κυτταροκαλλιεργειες θηλαστικου χρησιμοποιωντας γλυκοκορτικοειδη
JP2013524825A5 (OSRAM)
HRP20220107T1 (hr) Proteini koji vežu kalikrein plazme
WO2012171030A3 (en) Method and apparatus for antibody production and purification
RU2015144020A (ru) Среды для культивирования клеток и способы получения антител
JP2017538446A5 (OSRAM)
ZA200904482B (en) Polyelectrolyte precipitation and purification of antibodies
JP2015521848A5 (OSRAM)
TW201341030A (zh) 絮凝方法
TR201610497T1 (tr) Rekombi̇nant protei̇n galaktosi̇lasyonunu kültür ortaminin opti̇mi̇zasyonu vasitasiyla modüle etme yöntemi̇
MY184072A (en) Increasing virus like particle yield in plants
RU2017101195A (ru) Способы культивирования клеток и среды, предусматривающие n-ацетилцистеин
ES2812923T3 (es) Método para preparar una disolución acuosa que contiene medio de cultivo y agente quelante